A graduate of Harvard Medical School, Elliott Bennett-Guerrero is a professor and vice-chairman of Stony Brook Medicine's department of anesthesiology. Elliott Bennett-Guerrero has conducted several studies related to COVID-19 including the use of convalescent blood plasma. A randomized clinical trial he led was published in the journal Critical Care Medicine: Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial. Critical Care Medicine. 2021 Jul 1;49(7):1015-1025. PMID: 33870923. Convalescent blood plasma treatment has been used for patients that have the COVID-19 virus, however, studies have not shown it to be beneficial in most hospitalized patients. It involves plasma transfusion from people who have already recovered from the condition. The treatment and therapy is likely to be most beneficial in people that are in the early stage of the condition or who have a weak immune system and cannot mount their own antibody response to the infection. The therapy can have rare side effects and risks that include allergic reactions . Although it can have risks, there were more than 500,000 people treated in the United States with the therapy and few felt any side effects.

1. Convalescent Blood Plasma Treatment for COVID-19
Elliott Bennett-Guerrero

2. Introduction
A graduate of Harvard Medical School, Elliott Bennett-Guerrero is a professor and vice-
chairman of Stony Brook Medicine's department of anesthesiology. Elliott Bennett-
Guerrero has conducted several studies related to COVID-19 including the use of
convalescent blood plasma. A randomized clinical trial he led was published in the
journal Critical Care Medicine: Convalescent Plasma Versus Standard Plasma in
Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind
Randomized Trial. Critical Care Medicine. 2021 Jul 1;49(7):1015-1025. PMID: 33870923.

3. Convalescent blood plasma treatment has been used for patients that have the COVID-
19 virus, however, studies have not shown it to be beneficial in most hospitalized
patients. It involves plasma transfusion from people who have already recovered from
the condition. The treatment and therapy is likely to be most beneficial in people that
are in the early stage of the condition or who have a weak immune system and cannot
mount their own antibody response to the infection.

4. The therapy can have rare side effects and risks that include allergic reactions .
Although it can have risks, there were more than 500,000 people treated in the United
States with the therapy and few felt any side effects.